Clasado Biosciences has announced that its prebiotic ingredient Bimuno® GOS is now available for use in Therapeutic Goods Administration (TGA)-listed products in Australia, including dietary supplements intended for therapeutic purposes.
The development allows dietary supplements marketed under the TGA framework to include Bimuno GOS and display its range of permitted health claims.
David Mharakurwa, Regional Director APAC at Clasado said, “This is a major step forward for Bimuno GOS in Australia. Formulators now have the opportunity to include the most studied GOS on the market, in therapeutic products that align with consumer demand for credible, gut-focused health solutions. And with permitted claims available under TGA regulation for products containing Bimuno GOS, it makes it easier to communicate those benefits clearly and confidently to consumers.”
This move into the TGA category builds on the ingredient’s existing success within the FSANZ (Food Standards Australia New Zealand) category, where 29 self-substantiated food-health relationship claims are available, further strengthening its regulatory position in the region.
Australia represents one of the world’s most progressive supplement markets, valued at US$13.74 billion in 2023. Prebiotics are seeing a strong growth curves in particular according to Grand View Research data, with the category expected to triple in value to US$708 million by 2030, at an impressive CAGR of 17.6%.
With a clinically proven low dose starting from just 1.37g, Bimuno GOS combines formulation flexibility with a strong scientific profile backed by more than 125 publications and over 20 clinical trials.
David added that this development provides Australian formulators with the tools to deliver next-generation prebiotic gut health products that meet the highest consumer and regulatory expectations.
